Medical diagnostics
Medical diagnostics is undergoing a rapid transformation driven by an ageing population and the surge in chronic and infectious diseases. Testing is shifting from centralized to point-of-care, enabling immediate results. Early disease diagnosis is gaining traction, particularly in emerging economies. Automation, including automated analyzers and rapid point-of-care diagnostics, is streamlining processes. Specialized disease-specific biomarkers and companion diagnostics are reshaping precision medicine. Emerging markets present significant growth opportunities.
Key trends
- Point-of-care testing
- Early disease diagnosis
- Specialized disease-specific biomarkers
Problem with conventional methods
- Require highly-skilled technicians
- Unsuitable for point-of-care analyses
- Demand laborious pretreatment
- Slow response time
Canatu electrochemical biosensors
- Fast response
- Highest sensitivity
- Excellent accuracy / specificity
- Easy handling
Conventional analytical methods create challenges
Conventional analytical methods used for medical diagnostics are based on chromatographic techniques, which provide sensitive and selective detection. However, these techniques require highly skilled technicians, they are unsuitable for point-of-care analysis, and demand laborious pretreatment of samples to extract the compound analyzed from the matrix, which is time consuming risking patient care.
Electrochemical biosensors provide the solution
Electrochemical biosensors hold the potential to transform medical diagnostics by delivering fast response, high sensitivity, excellent accuracy, low cost, easy handling, and field applicability. These electrochemical biosensors make inexpensive and immediate testing possible which means paramedics can make better-informed decisions at the point of care. As a result, saving lives will no longer be contingent on cost of care or lack of information.
Using the most advanced carbon nanotubes from Canatu on the electrode surface further enhances the performance of these electrochemical biosensors, delivering the highest sensitivity in the industry. Canatu CNT offers a versatile and proven material platform for electrochemical biosensors that can be tailored for specific immobilization protocols ensuring high sensitivity for select redox reporters.
Electrochemical biosensors
Canatu has developed a point-of-care assay for the quantitative detection of different substances from ultra-low concentrations. This assay employs disposable test strips utilizing Canatu CNT. The inherent properties of Canatu CNTs, including their large surface area, high conductivity, and customizable surface chemistry, establish them as an ideal electrode material for electrochemical biosensors.
Download technical data
We are seeking partnerships with forerunner companies to bring lab-level testing anywhere. Download our technical data to explore our capabilities further.
Download technical data
Latest research
While our experts solve the issues of today, they are also working on what’s to come. Currently, we are developing our versatile and proven material platform to transform electrochemical detection, leveraging the exceptional purity of our Canatu CNTs. This results in remarkable analytical performance across diverse sectors, including medical diagnostics, environmental monitoring, agriculture, and neuroscience.
Lab on a strip
Opioid misuse and access to care continue to be key challenges. Painkillers are some of the most misused drugs. Every year, 15 million people misuse opioids in the EU and US, and more than 68,000 people in US alone die from opioid-involved overdoses. The economic cost of opioid crisis is 78,5 billion dollars annually in US.
Currently, there are no fast and reliable means for measuring opioid concentrations at the point of use. Simpler and inexpensive lab-level tests with rapid results are needed, to equip on-site caregivers with better means to determine best patient care. Accurate and safe dosing of opioids is critical for safe patient care; to relieve pain effectively, to prevent dependency and to prevent lethal overdoses.
Canatu’s solution brings the medical laboratory anywhere, making sure saving lives is no longer about cost of care or lack of information.
Saving lives is no longer about cost of care or lack of information.
A market survey carried out by Canatu revealed that almost 70% of health care professionals would use rapid opioid sensors if they were approved for use by regulatory authorities.
Canatu advances point-of-use sensors for rapid medical diagnostics with forerunner companies, research partners and a leading Finnish University Hospital, together transforming products for better tomorrows with nano carbon.
We partner with forerunner companies ready to transform industries
Contact our specialist in medical diagnostics
Send us a message
We are looking for a partner for product development and commercialization. If you’re interested in exploring this opportunity further, contact our CTO Ilkka Varjos.
Related content
While our experts solve the issues of today, they are also working on what’s to come. Currently, our technology for electrochemical sensors is developing fast. Because of the exceptional purity of Canatu CNTs, remarkable analytical performance can be attained in various sectors such as clinical analysis, environmental monitoring, agriculture and neuroscience. Learn more.
The inherently large surface area, high conductivity and tailorable surface chemistry makes Canatu CNT an ideal electrode material for electrochemical sensors. See the product.
Canatu CNT offers a versatile material platform for electrochemical detection. Electrochemical sensors using Canatu CNTs have the potential to provide resilient, accurate, reliable, and low-cost analysis in clinical, industrial, environmental, food safety and agricultural sectors. See the platform.
Electrochemical sensors for bedside blood concentration measurement progress to clinical studies. The new point-of-use measurement enables real-time detection of analgesics from blood without extensive sample treatment, improving test result wait time, cost and convenience. See press release.
Finnish ecosystem spurs diagnostics development. Canatu will develop a new hybrid electrochemical sensor for target detection and drug concentration measurement. See press release.
Canatu creates nano solutions for massive impact. We work with carbon, the most versatile material in the universe, and collaborate with other forerunner companies to make breakthrough innovations. See our company.
Canatu partners with forerunner companies, research partners and a leading Finnish University Hospital, together transforming products for better tomorrows with nano carbon. See how we collaborate for an impact.
